DRKS00001856
Recruiting
Not Applicable
Diagnostic precision of in vitro diagnostics in predicting a therapeutic outlook in patients with recurrent ovarian cancer (predictor study) - Predictor-Study
TherapySelect GmbH & Co KG0 sites260 target enrollmentDecember 14, 2012
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- C56
- Sponsor
- TherapySelect GmbH & Co KG
- Enrollment
- 260
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients \= 18 years with a histologically verified ovarian cancer
- •\- Patients must have elevated CA 125 levels (\> 70 U/ml); a follow\-up of these laboratory parameters must be medically indicated
- •\- In the case of first\-time affection:
- •o A chemotherapy carboplatin and paclitaxel is indicated
- •\- In the case of a recurrence:
- •o Pre\-treatment with platinum\-based mono or combination therapy
- •o A mono\-therapy consisting of topotecan or liposomal doxorubicin (e.g. Caelyx®) is indicated (no progression having previously occurred while using the applied substance)
- •\- A puncture to extract the existing ascites or preural effusion and/or a surgical intervention for the extraction of tumor tissue must be medically indicated
- •\- Patients must geographically situated in a manner to be able to participate in treatment
- •\- Tumor cell count of the extracted ascites/preura punctate or tumor tissue: \= 5 x 106 cells
Exclusion Criteria
- •\- Ovarian tumors with low malignant potential (e.g. borderline tumors)
- •\- Non\-epithelial ovarian tumors or mixed tumors (e.g. Mueller'scher mixed tumor)
- •\- Patients who have received radiation therapy and/or chemotherapy and/or immunotherapy within three weeks prior to puncture
- •\- Patients who have had another diagnosed malignancy within the past 5 years which could not be resolved through surgery alone (except CIS of the cervix or adequately treated basal cell carcinoma of the skin)
- •\- The concurrent application of another neoplastic therapy (chemotherapeutics, hormone therapeutics, or immunotherapeutics), or concurrent radiotherapy during the course of treatment of the study (hormone replacement therapy (HRT), steroid antiemetics, for example, are permitted)
- •\- Dementia or a severe change in mental status impairing the patient's ability to comprehend the study or to consent to participation
- •\- Pregnant or lactating women
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
ipid profile accuracy in the diagnosis of exudative pleural effusioPleural effusion.Pleural effusion in conditions classified elsewhereIRCT2015083112642N18Vice Chancellor for Research and Technological Shahid Beheshti University of Medical Sciences40
Not yet recruiting
Not Applicable
A study on Diabetic foot managementHealth Condition 1: O- Medical and SurgicalCTRI/2024/02/062727SRM medical college hospital and research center
Completed
Not Applicable
Accuracy and limitation of diagnostic tools for infective endocarditisI33.0Acute and subacute infective endocarditisDRKS00029037niversitätsklinikum Regensburg96
Recruiting
Not Applicable
Evaluation of the accuracy of diagnosis by Endocytosopy in SNADETSNADETJPRN-UMIN000043355Endoscopy Division, National Cancer Center Hospital50
Completed
Not Applicable
Accuracy of endoscopy and histology in diagnosing superficial esophageal cancer.JPRN-UMIN000004529Osaka Medical Center for Cancer and Cardiovascular Diseases110